Professor – Director of the Department of Lymphoma Medicine, specializing in the diagnosis and treatment of lymphoma and cellular immunotherapy.
Affiliated HospitalFudan University Cancer Hospital
→
Research areas: Clinical diagnosis and treatment of lymphoma, autologous hematopoietic stem cell transplantation, CAR-T cell immunotherapy, and promotion of specialized diagnosis and treatment models for lymphoma.
Cutting-edge Technology: The Department of Lymphoma, leading the way, is one of the earliest established clinical specialties for lymphoma in China. It pioneered the breaking down of traditional comprehensive treatment limitations, promoting a specialized lymphoma treatment model. It is now a nationally renowned lymphoma treatment center and a center for hematopoietic stem cell transplantation and cell immunotherapy for lymphoma. It has led/participated in over 300 domestic and international clinical registration studies, accounting for over 75% of China's new lymphoma drug development. It has facilitated the approval and marketing of 31 new anti-lymphoma drugs or new indications in China and promoted the approval of the first domestically produced innovative anti-lymphoma drug for marketing in the United States. In 2011, the CDE (Center for Drug Evaluation) announced that it led the most projects nationwide.
Diseases specializing in: lymphoma, Hodgkin's lymphoma, and non-Hodgkin's lymphoma.
Academic Highlights and Core Values: Chief Physician, Doctoral Supervisor, Party Secretary of Peking University Cancer Hospital, Director of the Department of Medical Oncology, and Director of the Department of Lymphoma. Standing Director of the Chinese Society of Clinical Oncology (CSCO), Chairman of the Chinese Anti-Lymphoma Alliance, Standing Committee Member of the Oncology Branch of the Chinese Medical Association, and Head of the Hematologic Oncology Group of the Expert Committee on Capacity Building and Continuing Education of Oncology of the National Health Commission. Recipient of the State Council Special Allowance and the 13th WuXi AppTec Life Chemistry Award. He has presided over one major new drug development project under the National Science and Technology Major Project, one "3" Foundation project, one sub-project of the "973" Program, and five National Natural Science Foundation of China projects. He holds a leading position nationwide in the specialized diagnosis and treatment of lymphoma and cellular immunotherapy, and has promoted the inclusion of Chinese lymphoma diagnosis and treatment experience in global guidelines.